Mallinckrodt is a global biopharmaceutical company consisting of multiple wholly owned subsidiaries that develop, manufacture, market, and distribute specialty pharmaceutical products and therapies. The company's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Following a period of financial restructuring, Mallinckrodt continues to focus on serving patients with severe and critical conditions.
Serves as the company's global corporate and legal headquarters, overseeing international operations, corporate governance, financial reporting, and housing key administrative functions.
Located in a modern business park designed to support international pharmaceutical operations and corporate management.
Emphasizes global collaboration, innovation in pharmaceuticals, adherence to international regulatory standards, and a strong focus on compliance and patient outcomes.
Central point for global strategy, financial oversight, and the legal framework of the company. Its location in Ireland supports its international business operations and access to European markets.
Mallinckrodt supports global operations focusing on the development, manufacturing, and commercialization of specialty branded pharmaceuticals and therapies. This includes research and development activities, clinical trials, regulatory affairs, supply chain management, and marketing and sales across key markets, primarily in North America and Europe, with distribution to other international regions.
College Business & Technology Park, Cruiserath, Blanchardstown
Dublin
Dublin 15
Ireland
Address: 1425 U.S. Route 206, Bedminster, New Jersey 07921
Primary hub for U.S. operations, strategic decision-making for the North American pharmaceutical market, and coordination of U.S.-based research, development, and commercial activities.
Address: First Floor, Block C, The Crescent, Skerne Road, Richmond, Surrey, TW9 2PU
Serves as the legal registered address for the public limited company, supporting corporate governance and UK-specific administrative requirements.
Address: Hazelwood or Webster Groves (various facilities in the area)
Key manufacturing and R&D hub, particularly for Mallinckrodt's specialty generics segment and API production, contributing to the company's global supply chain.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Mallinckrodt Pharmaceuticals' leadership includes:
Mallinckrodt Pharmaceuticals has been backed by several prominent investors over the years, including:
Following its emergence from Chapter 11 restructuring in November 2023, Mallinckrodt confirmed its leadership team, including the key appointment of a new Chief Financial Officer. Some executive transitions also occurred during the restructuring period.
Discover the tools Mallinckrodt Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Mallinckrodt commonly uses the 'first.last' email format for its employees. Variations might exist for very common names or specific departments, but this is the most prevalent structure.
[first].[last]@mallinckrodt.com
Format
jane.doe@mallinckrodt.com
Example
85%
Success rate
Mallinckrodt Press Release • April 2, 2024
Mallinckrodt announced the presentation of new data on Terlipressin, emphasizing its real-world effectiveness and clinical benefits for adults suffering from hepatorenal syndrome, at the upcoming EASL Congress 2024....more
Mallinckrodt Press Release • March 7, 2024
Mallinckrodt highlighted its commitment to patients with rare diseases by acknowledging and supporting various patient advocacy organizations on Rare Disease Day 2024, emphasizing its focus on addressing unmet medical needs....more
PR Newswire (covering Mallinckrodt Press Release) • November 15, 2023
Mallinckrodt plc announced it has successfully completed its financial restructuring process and emerged from Chapter 11, strengthening its financial foundation and positioning the company for long-term growth and to continue serving patients....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Mallinckrodt Pharmaceuticals, are just a search away.